The management of dyslipidemia is still a challenge in the medical community due to the limitations posed by statins when higher doses are demanded.

Ecostatin, is an investigational fixed dose combination of a statin and the hepatoprotective agent (AVVA01), aiming to the enhancement of statin effect, thus limiting the need of dose tittering and higher strengths, often associated with disproportional efficacy to side effect ratio.